Another CD20/CD3 bispecific is entering the fold, except this time for autoimmune diseases.
Prolific biotech creator Third Rock Ventures and Arie Belldegrun’s Two River have …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Nearly a decade ago, venture capitalist Bob Nelsen called industry veteran Vicki Sato to pitch her on launching a large company dedicated to tackling the
Plus, news about Nicox, Soleus and Molecular Templates: Akeso Biopharma’s $250M placement: The Hong Kong-based company, which is developing a closely watched bispecific antibody with
Scientists from Trinity College Dublin have made an important breakthrough that offers promise for developing new immune therapies for cancer.